SEC Filing Summary: BioSig Technologies, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioSig Technologies, Inc. on February 16, 2018. The filing reports the entry into a Material Definitive Agreement involving a private placement of equity securities. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
The filing details a capital raise transaction rather than periodic financial performance metrics. Key transaction figures include:
- Total Consideration Raised: $1,500,000.
- Securities Issued: 1,000 shares of Series E Preferred Stock and warrants to purchase 500,000 shares of Common Stock.
- Preferred Stock Terms: Par value $0.001; Stated value $1,500 per share; 7% cumulative annual dividends; conversion price of $1.50 per share.
- Warrant Terms: Exercise price of $1.75 per share; exercisable immediately; expiration date August 16, 2021.
- Consent Warrants: 100,000 warrants issued to Series D Holders with an exercise price of $1.50 per share, expiring February 14, 2021.
The filing text does not provide clear values for revenue, profit, cash flow, operating margins, total debt, or liquidity positions as this is a transaction-specific report.
Material Changes and Agreements
The primary material change is the execution of a Securities Purchase Agreement with institutional accredited investors. Key contractual provisions include:
- Right of First Refusal (ROFR): Investors have a 12-month ROFR to purchase 30% of any subsequent securities offerings by the Company.
- Registration Rights: The Company agreed to file a registration statement within 90 days covering the resale of Preferred Shares, Warrants, and related securities.
- Anti-Dilution Protection: Both the Series E Preferred Stock and the Warrants include "full ratchet" anti-dilution adjustments if the Company issues equity at a price lower than the applicable conversion or exercise price.
- Liquidation Preference: Series E holders are entitled to the Stated Value plus accrued dividends in the event of liquidation.
Outlook, Risks, and Contingencies
Management commentary is limited to the terms of the transaction. The filing highlights the following risks and contingencies:
- Dilution Risk: The "full ratchet" provisions create significant potential for dilution to existing shareholders if the Company raises capital at a price below $1.50 or $1.75 per share.
- Series D Consent: Existing Series D Holders consented to the transaction and were granted the option to receive more favorable terms until April 17, 2018, in exchange for Consent Warrants.
- Dividend Obligation: The Company has a contractual obligation to pay 7% cumulative dividends on the Series E Preferred Stock upon conversion.
Investor Verification Checklist
- Verify the impact of the "full ratchet" anti-dilution provisions on existing common stock ownership.
- Confirm the Company's ability to file the required registration statement within the 90-day window.
- Assess the potential cash outflow or equity dilution associated with the 7% dividend obligation upon conversion of Series E shares.
- Review the full text of the Securities Purchase Agreement and Certificate of Designations for additional covenants not summarized here.
- Monitor whether Series D Holders elect to participate in the more favorable terms of the Series E transaction.